PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2134003
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2134003
Artificial Intelligence in IVD Market size was valued at US$ 510.3 Million in 2025, expanding at a CAGR of 20.9% from 2026 to 2033.
Artificial Intelligence in IVD includes algorithms, machine-learning software, computational pathology, intelligent laboratory informatics, and AI-enabled analytical workflows to interpret or support results generated from patient specimens. In contrast to traditional IVD, where measurements are primarily based on assay chemistry and instrumentation, AI adds a computational layer that can recognize patterns, integrate multimodal data, prioritize cases, and support diagnosis. Thus, the ecosystem includes laboratory instruments, software platforms, data infrastructure, validation, implementation, and lifecycle services across pathology, molecular diagnostics, hematology, and related workflows. In 2025, the U.S. FDA approved over 1,300 AI-enabled medical devices, a testament to the regulatory maturity surrounding clinical AI technologies. This is driving the market away from stand-alone algorithms and toward integrated, clinically governed diagnostic workflows.
Artificial Intelligence in IVD Market- Market Dynamics
Convergence of Multimodal Diagnostic Data With AI-Assisted Clinical Workflows
The need to translate increasingly fragmented diagnostic information into clinical intelligence that can be used is a key market driver. Laboratory results, pathology images, genomic findings, and clinical records are rarely analyzed in isolation, causing bottlenecks in workflow that AI may alleviate through automated summarization, pattern recognition, and decision support. Roche's 2025 Diagnostics Day materials pointed out how computational systems can lower the manual information-processing requirements, noting a 40-50% reduction in the time to summarize oncology cases with an AI-enabled abstraction tool. This is especially true for IVD, where the diagnostic value increasingly derives from integrating assay outputs with contextual patient information rather than producing a further laboratory result. This implies an increased need for interoperable AI software, verified data pipelines, and human-supervised interpretation.
The Global Artificial Intelligence in IVD Market is segmented on the basis of Component, Diagnosis Type, Modality, Technology, End User, and Region.
By component, components in AI-enabled IVD are shifting from being driven solely by the algorithm to being determined by how intelligence is embedded across the entire diagnostic workflow. Software provides algorithmic interpretation, workflow orchestration, data integration, and decision-support functionality; hardware supplies the computational and laboratory infrastructure for image acquisition, high-throughput testing, and AI-enabled processing. Where labs need validation, implementation, model maintenance, cybersecurity, interoperability, and specialist support, services become important. For example, PathAI announced in March 2025 its expansion of the AISight digital pathology platform with four new laboratory partners, demonstrating how software-led ecosystems can scale AI capabilities across multiple laboratory environments. The component structure, therefore, increasingly favors integrated platforms in which hardware, software, and ongoing services work together as a coordinated diagnostic infrastructure.
By diagnosis type, diagnostic applications differ significantly in their AI needs by diagnosis type, as the underlying evidence ranges from images and physiological signals to molecular information extracted from tissue. High-volume image analysis and automated detections have positive effects on radiology and chest and lung imaging. Quantitative interpretation of cardiovascular measurements is essential for cardiology. Pattern recognition is required in complex imaging and clinical datasets in neurology. Oncology increasingly relates pathology, biomarkers, and molecular information for precision treatment decisions. This concentration is reflected in the AI devices approved in China through June 2025: 68.8% of 154 approved AI-based medical devices were related to radiology, compared to 10.4% for cardiology. The distribution suggests that data-rich and highly structured diagnostic workflows are the strongest base for AI deployment today.
Artificial Intelligence in IVD Market- Geographical Insights
The United States is leading market because AI-enabled diagnostics are being developed in a relatively mature regulatory and clinical-technology ecosystem. In 2025, the FDA's work on AI lifecycle management, predetermined change control mechanisms, post-market performance considerations, and authorization of AI-enabled devices provided more clarity to developers about how to iteratively improve their software. In just the 2025 CDRH/OCE report from the FDA, there were 26 IVD authorizations, including new and expanded companion-diagnostic indications. This is especially true in the case of AI in IVD, where algorithms must be compatible with validated assays, pathology workflows, and clinical decision processes. The confluence of regulated AI development and an established companion-diagnostics environment is especially important. Thus, U.S. competition is turning more to clinically validated integration, and away from just algorithmic capability.
China is a separate growth center, with a focused development of AI devices, domestic technology suppliers, and an increasingly structured regulatory pathway. A study of approvals through June 2025 revealed 20 AI-based medical-device approvals in the first half of 2025, with radiology continuing as the most common application area. The country's regulatory environment is also leaning toward more explicit lifecycle management of AI-powered medical devices. The NMPA's 2025 measures called for more refined review requirements, including consideration of multi-disease and large-model AI applications and simplified changes where core algorithms are unchanged. In the IVD AI space, this environment benefits companies that can validate locally, work through the regulations, and plug into China's fast-growing diagnostic technology ecosystem more than those competing on model performance alone.
Competitive positioning is now based on the capacity to combine diagnostic hardware, knowledge of assays, AI algorithms, clinical validation, and laboratory workflow infrastructure. Roche and Leica Biosystems, part of Danaher, offer well-established IVD and pathology platforms, whereas companies such as PathAI and Tempus provide algorithmic and computational capabilities. Roche's approach to partnering in the field shows how important it is to build an ecosystem: the company announced 75 new diagnostic agreements in 2025, highlighting collaboration as a way of expanding its digital and AI capabilities. On the product side, Roche has incorporated AI into computational pathology and companion diagnostics, and Danaher's 2025 partnership with AstraZeneca was specifically aimed at digital and computational pathology and AI-assisted algorithms. The source of competitive advantage is therefore moving toward integrated, validated AI-diagnostic platforms that have scalable laboratory connectivity.
In April 2025, Roche was granted FDA Breakthrough Device Designation for the VENTANA TROP2 RxDx Device. This device uses AI for pathology and helps diagnose non-small cell lung cancer. It was the first time an FDA Breakthrough Device Designation was awarded to a computational pathology companion diagnostic device.
In June 2025, PathAI received FDA clearance for AISight Dx, a pathology platform that assists with primary diagnoses. The clearance also included a Predetermined Change Control Plan, known as PCCP, which allows PathAI to add approved updates to the platform in the future.